Oxford University Clinical Research Unit Indonesia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Monash University Indonesia, Tangerang Selatan, Indonesia.
Oxford University Clinical Research Unit Indonesia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Lancet Glob Health. 2023 Sep;11(9):e1412-e1421. doi: 10.1016/S2214-109X(23)00312-1.
The impact of the COVID-19 pandemic on tuberculosis control in high-burden countries has not been adequately assessed. We aimed to estimate the impact of the COVID-19 pandemic on the national tuberculosis programme in Indonesia, in association with indicators of human development and health-system capacity across all 514 districts in 34 provinces.
We did a nationwide longitudinal analysis to compare tuberculosis case notification, treatment coverage, and mortality rates in Indonesia before (2016-19) and during (2020-21) the COVID-19 pandemic. The following outcomes were assessed: the district-level quarterly reported tuberculosis case notification rate (number of all reported tuberculosis cases per 100 000 population), treatment coverage (proportion of tuberculosis patients who started treatment), and all-cause mortality rate in patients with tuberculosis (number of reported deaths per 100 000 population). District-level data on COVID-19 incidence and deaths, health-system capacity, and human development and sociodemographics were also analysed. Multilevel linear spline regression was done to assess quarterly time trends for the three outcomes.
During the COVID-19 pandemic, the tuberculosis case notification rate declined by 26% (case notification rate ratio 0·74, 95% CI 0·72-0·77) and treatment coverage declined by 11% (treatment coverage ratio 0·89, 95% CI 0·88-0·90), but there was no significant increase in all-cause mortality (all-cause mortality rate ratio 0·97, 95% CI 0·91-1·04) compared with the pre-pandemic period. In the second year of the pandemic, we observed a partial recovery of the case notification rate from Q1 to Q4 of 2021, a persistent decrease in treatment coverage, and a decrease in the all-cause mortality rate from Q2 of 2020 to Q4 of 2021. The multivariable analysis showed that the reduction in the tuberculosis case notification rate was associated with a higher COVID-19 incidence rate (adjusted odds ratio 3·1, 95% CI 1·1-8·6, for the highest compared with the lowest group) and fewer GeneXpert machines for tuberculosis diagnosis (3·1, 1·0-9·4, for the lowest compared with the highest group) per 100 000 population. The reduction in tuberculosis treatment coverage was associated with higher COVID-19 incidence (adjusted odds ratio 11·7, 95% CI 1·5-93·4, for the highest compared with the lowest group), fewer primary health centres (10·6, 4·1-28·0, for the lowest compared with the middle-high group), and a very low number of doctors (0·3, 0·1-0·9, for the low-middle compared with the lowest group) per 100 000 population. No factors were shown to be significantly associated with all-cause mortality.
The COVID-19 pandemic adversely and unevenly affected the national tuberculosis programme across Indonesia, with the greatest impacts observed in districts with the lowest health-system capacity. These disruptions could lead to an escalation in tuberculosis transmission in the coming years, warranting the need for intensified efforts to control tuberculosis and strengthen local health systems.
Wellcome Africa Asia Programme Vietnam.
For the Bahasa translation of the abstract see Supplementary Materials section.
COVID-19 大流行对高负担国家结核病控制的影响尚未得到充分评估。我们旨在评估 COVID-19 大流行对印度尼西亚国家结核病规划的影响,同时评估与所有 34 个省的 514 个区的人类发展和卫生系统能力相关的指标。
我们进行了全国性的纵向分析,以比较 COVID-19 大流行之前(2016-19 年)和期间(2020-21 年)印度尼西亚的结核病病例报告率、治疗覆盖率和全因死亡率。评估了以下结果:每 10 万人报告的结核病病例数(每 10 万人报告的所有结核病病例数)的区县级季度报告结核病病例报告率、治疗覆盖率(开始治疗的结核病患者比例)和每 10 万人结核病患者的全因死亡率(每 10 万人报告的死亡人数)。还分析了区县级 COVID-19 发病率和死亡率、卫生系统能力以及人类发展和社会人口统计学数据。采用多水平线性样条回归评估了三个结果的季度时间趋势。
在 COVID-19 大流行期间,结核病报告率下降了 26%(病例报告率比 0.74,95%CI 0.72-0.77),治疗覆盖率下降了 11%(治疗覆盖率比 0.89,95%CI 0.88-0.90),但全因死亡率没有显著增加(全因死亡率比 0.97,95%CI 0.91-1.04)与大流行前时期相比。在大流行的第二年,我们观察到 2021 年第一季度到第四季度结核病报告率的部分恢复,治疗覆盖率持续下降,以及 2020 年第二季度到 2021 年第四季度全因死亡率的下降。多变量分析表明,结核病报告率的下降与更高的 COVID-19 发病率(调整后的比值比 3.1,95%CI 1.1-8.6,与最低组相比最高组)和每 10 万人诊断结核病的 GeneXpert 机器更少(3.1,1.0-9.4,与最低组相比最高组)相关。结核病治疗覆盖率的下降与更高的 COVID-19 发病率(调整后的比值比 11.7,95%CI 1.5-93.4,与最高组相比最低组)、初级保健中心更少(10.6,4.1-28.0,与中间高组相比最低组)和医生人数非常少(0.3,0.1-0.9,与低中组相比最低组)有关每 10 万人。没有发现任何因素与全因死亡率显著相关。
COVID-19 大流行对印度尼西亚全国结核病规划产生了不利和不均衡的影响,在卫生系统能力最低的地区影响最大。这些干扰可能导致未来几年结核病传播的加剧,需要加强结核病控制和加强地方卫生系统。
威康信托基金会非洲-亚洲计划越南分部。